Next Article in Journal
The Good Clinical Outcome for Patients with Acute Ischemic Stroke Treated with Mechanical Thrombectomy—Does Time Still Matter?
Next Article in Special Issue
The Psychoneurobiology of Insomnia: Hyperarousal and REM Sleep Instability
Previous Article in Journal / Special Issue
SLEEPexpert+: Blending Internet-Based Cognitive Behavioral Therapy for Insomnia with In-Person Psychotherapy—A Feasibility Study in Routine Care
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CTN
Volume 7
Issue 3
10.3390/ctn7030028
ctn-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2?

by
Rolf Fronczek
1,2 and
Gert Jan Lammers
1,2,*
1
Department of Neurology, Leiden University Medical Centre, 2300 RC Leiden, The Netherlands
2
Stichting Epilepsie Instellingen Nederland (SEIN), Sleep-Wake Centre, 2103 SW Heemstede, The Netherlands
*
Author to whom correspondence should be addressed.
Clin. Transl. Neurosci. 2023, 7(3), 28; https://doi.org/10.3390/ctn7030028
Submission received: 2 August 2023 / Revised: 11 September 2023 / Accepted: 15 September 2023 / Published: 19 September 2023
(This article belongs to the Special Issue Sleep–Wake Medicine)
Browse Figure
Versions Notes

Abstract

Nearly 25 years have passed since the ground-breaking discovery that hypocretin deficiency underlies human narcolepsy with cataplexy. Over time, it has become increasingly evident that hypocretin deficiency goes beyond the conventional core symptoms, or pentad, traditionally associated with narcolepsy. The emergence of hypocretin receptor 2 agonists presents an exciting opportunity, prompting us to explore the role of receptor 2 in the complete spectrum of NT1 symptoms. In this review, several clinical manifestations beyond the core symptoms will be discussed. We will outline what is currently known about the involvement of hypocretin receptors to reflect on what we expect with current knowledge from treatment with specific receptor agonists.
Keywords: hypocretin; orexin; narcolepsy hypocretin; orexin; narcolepsy

Share and Cite

MDPI and ACS Style

Fronczek, R.; Lammers, G.J. Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2? Clin. Transl. Neurosci. 2023, 7, 28. https://doi.org/10.3390/ctn7030028

AMA Style

Fronczek R, Lammers GJ. Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2? Clinical and Translational Neuroscience. 2023; 7(3):28. https://doi.org/10.3390/ctn7030028

Chicago/Turabian Style

Fronczek, Rolf, and Gert Jan Lammers. 2023. "Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2?" Clinical and Translational Neuroscience 7, no. 3: 28. https://doi.org/10.3390/ctn7030028

APA Style

Fronczek, R., & Lammers, G. J. (2023). Narcolepsy Type 1: Should We Only Target Hypocretin Receptor 2? Clinical and Translational Neuroscience, 7(3), 28. https://doi.org/10.3390/ctn7030028

Article Metrics

Back to TopTop